Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eight-week randomized double-blind study of GSK372475 versus paroxetine and placebo in adults with major depressive disorder
2005-003400-11Phase 2Terminated
- Sponsor
- GSK
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NS2359 in major depressive disorder (MDD) (3 arms), sponsored by GSK. Primary endpoint: Change in MADRS total score at Week 8. Started Sep 2005; status: terminated.
02
Drugs
NS2359
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2005-003400-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003400-11.